Cure8 research brief
This preclinical study suggests quince gel reduced inflammation, oxidative stress, and tissue injury in a rat model of ulcerative colitis and identifies quercetin as a likely active component. Findings point to possible complementary strategies for mucosal protection but are not evidence for use in patients yet.
Researchers in IBD drug-discovery and natural-product therapeutics; clinicians and patients curious about preclinical complementary therapies for ulcerative colitis.
This animal study tested an intrarectal quince (Cydonia oblonga) gel in a rat model of acetic-acid–induced ulcerative colitis. Over 10 days the treated group showed smaller macroscopic and histologic injury, lower markers of oxidative stress (TAS/TOS/OSI/MDA), and reduced serum inflammatory markers (CRP, TNF‑α, IL‑1β, IL‑6) versus untreated UC rats.
The authors identified quercetin among gel constituents by LC–MS/MS and used bioinformatics and molecular docking to highlight potential targets (TGFB1, STAT3, MMP9) and a predicted quercetin–TNF interaction. The study reports preclinical, mechanistic data rather than human clinical results.
The route was intrarectal gel in rodents, so dosing, safety, and efficacy in people are unknown. Bioinformatic and docking results suggest possible molecular interactions but are not clinical evidence.
Animal-model results and in silico docking generate hypotheses that need validation in human safety and efficacy studies before clinical use. The delivery method (intrarectal gel) and rat physiology limit direct applicability to people.
Review the original publication for the complete reporting, methods, and context.
Funding disclosed by the source: Dicle University Scientific Research Platform, award TIP.26.055; award TIP.26.055
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The study suggests a plant-derived AHR-activating mechanism that reduced inflammation and repaired the intestinal barrier in preclinical ulcerative colitis models, a pathway that could be relevant to future therapies or...
Researchers are exploring plant-derived polysaccharides as potential therapies that might reduce inflammation and protect the intestinal barrier. For people with UC, therapies that reduce pyroptosis and restore...
This study describes a local rectal therapy that combines mesalamine with probiotic‑derived extracellular vesicles to promote mucosal healing and reduce inflammation in ulcerative colitis models, which could point toward...
